- Latest weekly return ranks in the strongest part of its sector group.
RGC
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Regencell Bioscience Holdings Ltd · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
6.18 USD
8.0%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -72.8% below the Trend Line and sits at 2.6% of its 52-week range. The latest completed week returned 8.0%, after a -3.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 47/100 conviction, while the latest news-sentiment score is 38/100. Near-term considerations: volume confirmation is below normal; earnings are due in 88d.
Setup score
20
out of 100
Latest Close
6.18 USD
31 Jul 2026
1W Return
8.0%
latest completed week
4W Return
-3.0%
short-term follow-through
12W Return
-78.9%
quarterly tape
Trend Breadth
67.3%
35 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
8.0%
Latest completed week; four-week move -3.0%.
Indicator stack
37/24
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 32.66%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
47/100 conviction; expected move 33.6%.
News sentiment
38/100
40 relevant articles in the latest sentiment read.
Event risk
88d
Next report is scheduled for 28 Oct 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -72.8% below the Trend Line and sits at 2.6% of its 52-week range. The latest completed week returned 8.0%, after a -3.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0912-week average 0.36
12-week confirmation
Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.09Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -3.0% over four weeks, -78.9% over 12 weeks, and -52.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year35
Trend breadth67.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.46Latest activity-pressure read.
Pressure change2.1%Four-week change in activity pressure.
Leadership-71.42Latest relative-leadership reading.
RS change1.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 61%
Model confidence 58%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength41/100Blend of value, momentum, and quality. Underlying universe rank 60; rank 1 is best.
Value45/100Relative valuation strength. Underlying universe rank 56; rank 1 is best.
Quality44/100Profitability and accounting quality. Underlying universe rank 57; rank 1 is best.
Momentum46/100Medium-term price momentum. Underlying universe rank 55; rank 1 is best.
Growth46/100Revenue and earnings growth. Underlying universe rank 55; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -0.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
RGC shows volatility options pressure with a 47/100 conviction score, put-call volume ratio of 0.04, expected move of 33.6%, and Sharemaestro trend signal inactive.
Conviction47/100
Expected move33.6%
Put/call volume0.04
Insider activity-
No recent insider transactions are stored for this company.
News sentiment38/100
Weighted news tone is negative across 40 relevant articles.
1 positive · 23 neutral · 16 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings88dNext report is scheduled for 28 Oct 2026; event risk rises as the date approaches.
Options expected move33.6%Nearest-chain priced movement where available.
52-week drawdown-91.0%Distance below the 52-week high.
13-week volatility15.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher8 of 2618 weeks finished lower.
Best week+20.0%Week of 3 Apr.
Worst week-46.0%Week of 26 Jun.
Latest week+8.0%Week of 31 Jul.
Shape of recent returns
Strong gains7
Modest gains1
Flat weeks0
Modest losses4
Sharp losses14
Recent vol15.7%13-week weekly-return volatility.
Base vol22.6%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew16.8% / -10.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank62 / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Drug Manufacturers - Specialty & Generic
4-week rank39 / 74
Group average-1.5%
Trend breadth39.2%
Trend39.2%active weekly trend signals
MD54.1%positive activity pressure
RS32.4%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape24/100
Trend, activity pressure, participation, and risk combine to a 24/100 tape read.
Indicator analysis19/100Latest 12-week confirmation: trend 3/12, activity pressure 0/12, relative leadership 2/12.
Activity pressure 0.09; No reversal markers Next-Week ExpectancyNegative 32.66%Next-week expectancy is negative with a 32.66% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors43/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 51; Small Cap Core rank 57 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options34/100RGC shows volatility options pressure with a 47/100 conviction score, put-call volume ratio of 0.04, expected move of 33.6%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 33.6% Sentiment38/100Weighted news tone is negative across 40 relevant articles.
Regencell Bioscience Holdings Ltd (RGC) Cash Flow Insiders50/100No recent insider transaction evidence is stored.
Earnings88dNext report is scheduled for 28 Oct 2026; event risk rises as the date approaches.
Research flow3 items0 recent research articles and 3 Market Watch posts are available.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 6.18 USD | 8.0% | 22.73 USD | 8.17 USD | -1.46 | -71.42 | 908.1K | Off |
| 24 Jul 2026 | 5.72 USD | 13.9% | 23.21 USD | 8.13 USD | -1.44 | -73.64 | 1.3M | Off |
| 17 Jul 2026 | 5.02 USD | -14.6% | 23.73 USD | 8.10 USD | -1.42 | -77.48 | 1.7M | Off |
| 10 Jul 2026 | 5.88 USD | -7.7% | 24.22 USD | 8.07 USD | -1.44 | -75.00 | 3.4M | Off |
| 3 Jul 2026 | 6.37 USD | -1.7% | 24.58 USD | 8.04 USD | -1.50 | -72.73 | 4.4M | Off |
| 26 Jun 2026 | 6.48 USD | -46.0% | 24.91 USD | 8.00 USD | -1.57 | -72.54 | 2.2M | Off |
| 19 Jun 2026 | 12.01 USD | -36.2% | 25.08 USD | 7.96 USD | -1.57 | -52.03 | 891.4K | Off |
| 12 Jun 2026 | 18.83 USD | -5.8% | 25.09 USD | 7.89 USD | -1.42 | -25.17 | 448.4K | Off |
| 5 Jun 2026 | 19.99 USD | -16.4% | 24.88 USD | 7.77 USD | -1.08 | -18.90 | 462.0K | Off |
| 29 May 2026 | 23.90 USD | -7.4% | 24.65 USD | 7.65 USD | -0.64 | -7.69 | 455.2K | On |
| 22 May 2026 | 25.80 USD | -9.7% | 24.41 USD | 7.50 USD | -0.42 | 1.84 | 386.1K | On |
| 15 May 2026 | 28.58 USD | -2.4% | 24.08 USD | 7.34 USD | -0.30 | 14.62 | 515.4K | On |
| 8 May 2026 | 29.28 USD | 0.5% | 23.71 USD | 7.16 USD | -0.43 | 18.37 | 658.3K | On |
| 1 May 2026 | 29.12 USD | 5.9% | 23.29 USD | 6.97 USD | -0.55 | 25.68 | 445.2K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.